Video: Anti-Idiotypic antibodies for development of CAR T cell therapies Supported by: Published: 21 April 2022 Share this post 0 Share via Facebook Like Twitter Pinterest LinkedIn Digg Del Tumblr VKontakte Print Email Reddit Buffer Love This Weibo Pocket Xing Odnoklassniki WhatsApp Meneame Blogger Amazon Yahoo Mail Gmail AOL Newsvine HackerNews Evernote MySpace Mail.ru Viadeo Line Flipboard Comments Yummly SMS Viber Telegram Subscribe Skype Facebook Messenger Kakao LiveJournal Yammer Edgar Fintel Mix Instapaper Copy Link Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis. In this interview at the 11th EBF Open Symposium, Michael Schwenkert, Technical Sales Manager, Custom Antibodies, describes the challenges for the development of CAR T cell therapies that can be addressed using anti-idiotypic antibodies. He discusses how Bio-Rad generates custom antibodies for this purpose and for bioanalytical pharmacokinetic and immunogenicity assays.